Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations

Pain

Volumn 70, Issue 1, 1997, Pages 99-101

  Manfredi, Paolo L ^a   Borsook, David ^a   Chandler, Sonja W ^b   Payne, Richard ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

analgesia; cancer; methadone; oncology; opioid; pain

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE;

ADULT; ANALGESIA; ARTICLE; CANCER PAIN; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROMORPHONE; INJECTIONS, INTRAVENOUS; MALE; METHADONE; MORPHINE; PAIN; PALLIATIVE CARE; PERITONEAL NEOPLASMS; RETREATMENT; STOMACH NEOPLASMS;

EID: 0030888669     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(96)03313-1     Document Type: Article

References (16)

1. Babul, N., Darke, A.C. and Hagen, N., Hydromorphone metabolite accumulation in renal failure, J. Pain Sympt. Manag., 10 (1995) 184-186.
2. Beaver, W.T., Wallenstein, S.L., Houde, R.W. and Rogers, A., A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of oral and parenterally administered methadone, Clin. Pharmacol. Ther., 8 (1967) 415-426.
3. Crews, J.C., Sweeney, N.J. and Denson, D.D., Clinical efficacy of methadone in patients refractory to other mu opioid receptor analgesics for the management of terminal cancer pain, Cancer, 72 (1993) 2266-2272.
4. De Conno, F., Graff, L., Brunelli, C., Zecca, E., Ventafridda, V. and Ripamonti, C., Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients, J. Clin. One., 14 (1996) 2836-2842.
5. Fainsinger, R., Schoeller, T. and Bruera, E., Methadone in the management of cancer pain: a review, Pain, 52 (1993) 137-147.
6. Galer, B.S., Coyle, N., Pasternak, G.W. and Portenoy, R.K., Individual variability in the response to different opioids: report of five cases, Pain, 49(1) (1992) 87-91.
7. Gourlay, G.K., Cherry, D.A. and Cousins, M., A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer, Pain, 25 (1986) 297-312.
8. Houde, R.W., Clinical analgesic studies of hydromorphone, Adv. Pain Res. Ther., 8 (1986) 129-135.
9. Inturrisi, C.E., Colburn, W.A., Kaiko, R.F., Houde, R.W. and Foley, K.M., Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain, Clin. Pharmacol. Ther., 41 (1987) 392-401.
10. Jacox, A., Carr, D.B., Payne, R., et al., Management of Cancer Pain. Clinical Practice Guidelines No. 9, AHCPR Publication No. 94-0592, Rockville, MD, Agency for Health Care Policy and Research, U.S., Department of Health and Human Services, Public Health Service, March, 1994.
11. Leng, G. and Finnegan, M.J., Successful use of methadone in nociceptive cancer pain unresponsive to morphine, Palliat. Med., 8 (2) (1994) 153-155.
12. Levy, M.H., Pharmacologic treatment of cancer pain, N. Engl. J. Med., 335 (1996) 1124-1132.
13. Morley, J.S., Watt, J.W.G., Wells, J.C., Miles, J.B., Finnegan, M.J. and Leng, J., Methadone in pain uncontrolled by morphine, Lancet, 342 (1993) 1243.
14. Plummer, J.L., Gourlay, G.K., Cherry, D.A. and Cousins, M.J., Estimation of methadone clearance: application in the management of cancer pain, Pain, 33 (1988) 313-322.
15. Sawe, J., High dose morphine and methadone in cancer patients. Clinical pharmacokinetic consideration of oral treatment (review), Clin. Pharmacokinet., 11(2) (1986) 87-106.
16. Vigano, A., Fan, D. and Bruera, E., Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators, Pain, 67 (1996) 115-119.